CD79b

CD79b

a type I transmembrane protein on B cells that mediates signal transduction; expressed in B-cell tumors and B-cell acute leukoblastic leukemias.
References in periodicals archive ?
Collaborator ADC Progress: In June 2019, the FDA approved Polivy[TM] (polatuzumab vedotin-piiq) an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics' technology.
PRV-3279 is a humanized diabody (a bispecific scaffold biologic molecule) targeting the B-cell surface proteins, CD32B and CD79B, which has the potential to intercept the pathophysiology of systemic lupus erythematosus (SLE) and other B cell-mediated autoimmune diseases.
PRV-3279 is a humanized diabody targeting the B-cell surface proteins, CD32B and CD79B, which has the potential to intercept the pathophysiology of systemic lupus erythematosus and other B cell-mediated autoimmune diseases.
Food and Drug Administration (FDA) approval of Polivy (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics technology.
The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin's lymphoma, making it a promising target for the development of new therapies.
Polivy binds to a specific protein (called CD79b) found only on B cells (a type of white blood cell), then releases the chemotherapy drug into those cells.
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
Notably, all the 10 B cell gene signatures (BANK1, HVCN1, CD79B, RALGPS2, FCRL3, CD79A, BACH2, FCRL1, BLK, and BTLA) showed negative expression correlations with the PLK1 expression in ESCA, and 9 did in LUSC and STAD (Pearson correlation, FDR<0.1) (Figure 1(c)).
To compare the effects of these two types of MSCs on the composition and activation of lymphocytes infiltrated into SMGs, we examined the expression of various lymphocyte markers including B cell marker CD19; B/plasma cell markers CD79a, CD79b, and Ighg3; pan-T cell marker CD3e; helper T cell marker CD4; Treg marker Foxp3; Tfh marker inducible T cell costimulator (Icos) and its ligand Icosl; Th17 marker IL17; panAPC marker CD11c; follicular dendritic cell (FDC) marker CD21; and activated APC marker CD40, as well as those of immune inhibitory factors including TGF[beta]1-3 and IL10 by qRT-PCR.
They have a mature B-cell phenotype and typically express single or multiple immunoglobulin light chains and pan-B-cell antigens, such as CD19, CD20, CD22, and CD79b, but not CD21 (late B-cell marker).
B cells recognize antigens via the B cell receptor (BCR) composed of membrane-bound immunoglobulin (Ig) and the signal transducing component Iga (CD79a)/IgO (CD79b).
reported that somatic mutations in MYD88 and CD79B , the important upstream components of NF-?B signaling, were observed in 94.4% and 61.1% of PCNSLs, respectively.[sup][47] These findings indicate that aberrant somatic hypermutations may play a pathogenic role in PCNSL development.